Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9974189 | 0.90 | GPR119 (0.48) | GPR119PTPN2PTPN1PTPN6HTT | |
| SCHEMBL9937756 | 0.89 | GPR119 (0.63) | GPR119 | |
| SCHEMBL14244613 | 0.89 | GPR119 (0.51) | GPR119 | |
| SCHEMBL15034727 | 0.89 | GPR119 (0.47) | GPR119PTPN2PTPN1PTPN6HDAC1 | |
| SCHEMBL9974232 | 0.87 | GPR119 (0.45) | GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL9943189 | 0.87 | GPR119 (0.60) | GPR119 | |
| SCHEMBL9974230 | 0.87 | GPR119 (0.52) | GPR119 | |
| SCHEMBL14244635 | 0.86 | GPR119 (0.51) | GPR119 | |
| SCHEMBL14244615 | 0.86 | GPR119 (0.49) | GPR119 | |
| SCHEMBL14575369 | 0.86 | GPR119 (0.61) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012080476-A1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | GPR119, GPR3, MRGPRX2 | GPR119 1/4885PTPN2 2253/4885PTPN1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.